FGFR1 and cancer: Another MRTKi, infigratinib (a potent inhibitor of FGFR1-3) has also shown promising results in pre-clinical testing in vitro and in vivo, particularly against FP-RMS, but clinical testing has so far been restricted to adult cancer types (19, 20).